Personalized drug blitz before surgery aims to shrink tumors
NCT ID NCT05845450
Summary
This study is testing whether giving a short, personalized course of targeted drugs before surgery can help shrink tumors in people with early-stage colorectal cancer. Doctors first test the patient's tumor for specific genetic markers and then match them to one of several different drug treatments. The main goal is to see if this approach leads to a significant reduction or elimination of cancer cells in the surgically removed tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
RECRUITINGMilan, Lombardia/MI, 20133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.